Skip to main content
Top
Published in: BMC Cancer 1/2020

01-12-2020 | Hepatocellular Carcinoma | Research article

Texture analysis of MR images to identify the differentiated degree in hepatocellular carcinoma: a retrospective study

Authors: Mengmeng Feng, Mengchao Zhang, Yuanqing Liu, Nan Jiang, Qian Meng, Jia Wang, Ziyun Yao, Wenjuan Gan, Hui Dai

Published in: BMC Cancer | Issue 1/2020

Login to get access

Abstract

Background

To explore the clinical value of texture analysis of MR images (multiphase Gd-EOB-DTPA-enhanced MRI and T2 weighted imaging (T2WI) to identify the differentiated degree of hepatocellular carcinoma (HCC).

Method

One hundred four participants were enrolled in this retrospective study. Each participant performed preoperative Gd-EOB-DTPA-enhanced MR scanning. Texture features were analyzed by MaZda, and B11 program was used for data analysis and classification. The diagnosis efficiencies of texture features and conventional imaging features in identifying the differentiated degree of HCC were assessed by receiver operating characteristic analysis. The relationship between texture features and differentiated degree of HCC was evaluated by Spearman’s correlation coefficient.

Results

The grey-level co-occurrence matrix -based texture features were most frequently extracted and the nonlinear discriminant analysis was excellent with the misclassification rate ranging from 3.33 to 14.93%. The area under the curve (AUC) of the combined texture features between poorly- and well-differentiated HCC, poorly- and moderately-differentiated HCC, moderately- and well-differentiated HCC was 0.812, 0.879 and 0.808 respectively, while the AUC of tumor size was 0.649, 0.660 and 0.517 respectively. The tumor size was significantly different between poorly- and moderately-HCC (p = 0.014). The COMBINE AUC values were not increased with tumor size combined.

Conclusions

Texture analysis of Gd-EOB-DTPA-enhanced MRI and T2WI was valuable and might be a promising method in identifying the differentiated degree of HCC. The poorly-differentiated HCC was more heterogeneous than well- and moderately-differentiated HCC.
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-CANCER J CLIN. 2018;68(6):394–424.PubMedCrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-CANCER J CLIN. 2018;68(6):394–424.PubMedCrossRef
2.
go back to reference EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.CrossRef EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.CrossRef
3.
go back to reference Qiang L, Huikai L, Butt K, Wang PP, Hao X. Factors associated with disease survival after surgical resection in Chinese patients with hepatocellular carcinoma. World J Surg. 2006;30(3):439–45.PubMedCrossRef Qiang L, Huikai L, Butt K, Wang PP, Hao X. Factors associated with disease survival after surgical resection in Chinese patients with hepatocellular carcinoma. World J Surg. 2006;30(3):439–45.PubMedCrossRef
4.
go back to reference Shah SA, Greig PD, Gallinger S, Cattral MS, Dixon E, Kim RD, Taylor BR, Grant DR, Vollmer CM. Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg. 2006;202(2):275–83.PubMedCrossRef Shah SA, Greig PD, Gallinger S, Cattral MS, Dixon E, Kim RD, Taylor BR, Grant DR, Vollmer CM. Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg. 2006;202(2):275–83.PubMedCrossRef
5.
go back to reference Nagasue N, Uchida M, Makino Y, Takemoto Y, Yamanoi A, Hayashi T, Chang YC, Kohno H, Nakamura T, Yukaya H. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology. 1993;105(2):488–94.PubMedCrossRef Nagasue N, Uchida M, Makino Y, Takemoto Y, Yamanoi A, Hayashi T, Chang YC, Kohno H, Nakamura T, Yukaya H. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology. 1993;105(2):488–94.PubMedCrossRef
6.
go back to reference Martins A, Cortez-Pinto H, Marques-Vidal P, Mendes N, Silva S, Fatela N, Gloria H, Marinho R, Tavora I, Ramalho F, et al. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int. 2006;26(6):680–7.PubMedCrossRef Martins A, Cortez-Pinto H, Marques-Vidal P, Mendes N, Silva S, Fatela N, Gloria H, Marinho R, Tavora I, Ramalho F, et al. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int. 2006;26(6):680–7.PubMedCrossRef
7.
go back to reference Zhou L, Rui JA, Ye DX, Wang SB, Chen SG, Qu Q. Edmondson-Steiner grading increases the predictive efficiency of TNM staging for long-term survival of patients with hepatocellular carcinoma after curative resection. World J Surg. 2008;32(8):1748–56.PubMedCrossRef Zhou L, Rui JA, Ye DX, Wang SB, Chen SG, Qu Q. Edmondson-Steiner grading increases the predictive efficiency of TNM staging for long-term survival of patients with hepatocellular carcinoma after curative resection. World J Surg. 2008;32(8):1748–56.PubMedCrossRef
8.
go back to reference Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, Krieger NR, Schwartz ME. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl. 2004;10(4):534–40.PubMedCrossRef Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, Krieger NR, Schwartz ME. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl. 2004;10(4):534–40.PubMedCrossRef
9.
go back to reference Tamura S, Kato T, Berho M, Misiakos EP, O'Brien C, Reddy KR, Nery JR, Burke GW, Schiff ER, Miller J, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg. 2001;136(1):25–30 31.PubMedCrossRef Tamura S, Kato T, Berho M, Misiakos EP, O'Brien C, Reddy KR, Nery JR, Burke GW, Schiff ER, Miller J, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg. 2001;136(1):25–30 31.PubMedCrossRef
10.
go back to reference Huang K, Dong Z, Cai H, Huang M, Peng Z, Xu L, Jia Y, Song C, Li ZP, Feng ST. Imaging biomarkers for well and moderate hepatocellular carcinoma: preoperative magnetic resonance image and histopathological correlation. BMC Cancer. 2019;19(1):364.PubMedPubMedCentralCrossRef Huang K, Dong Z, Cai H, Huang M, Peng Z, Xu L, Jia Y, Song C, Li ZP, Feng ST. Imaging biomarkers for well and moderate hepatocellular carcinoma: preoperative magnetic resonance image and histopathological correlation. BMC Cancer. 2019;19(1):364.PubMedPubMedCentralCrossRef
11.
go back to reference Stigliano R, Burroughs AK. Should we biopsy each liver mass suspicious for HCC before liver transplantation?--no, please don't. J Hepatol. 2005;43(4):563–8.PubMedCrossRef Stigliano R, Burroughs AK. Should we biopsy each liver mass suspicious for HCC before liver transplantation?--no, please don't. J Hepatol. 2005;43(4):563–8.PubMedCrossRef
12.
go back to reference Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev. 2007;33(5):437–47.PubMedCrossRef Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev. 2007;33(5):437–47.PubMedCrossRef
13.
go back to reference Kogita S, Imai Y, Okada M, Kim T, Onishi H, Takamura M, Fukuda K, Igura T, Sawai Y, Morimoto O, et al. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol. 2010;20(10):2405–13.PubMedCrossRef Kogita S, Imai Y, Okada M, Kim T, Onishi H, Takamura M, Fukuda K, Igura T, Sawai Y, Morimoto O, et al. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol. 2010;20(10):2405–13.PubMedCrossRef
14.
go back to reference Nishie A, Yoshimitsu K, Okamoto D, Tajima T, Asayama Y, Ishigami K, Kakihara D, Nakayama T, Takayama Y, Shirabe K, et al. CT prediction of histological grade of hypervascular hepatocellular carcinoma: utility of the portal phase. Jpn J Radiol. 2013;31(2):89–98.PubMedCrossRef Nishie A, Yoshimitsu K, Okamoto D, Tajima T, Asayama Y, Ishigami K, Kakihara D, Nakayama T, Takayama Y, Shirabe K, et al. CT prediction of histological grade of hypervascular hepatocellular carcinoma: utility of the portal phase. Jpn J Radiol. 2013;31(2):89–98.PubMedCrossRef
15.
go back to reference Castellano G, Bonilha L, Li LM, Cendes F. Texture analysis of medical images. Clin Radiol. 2004;59(12):1061–9.PubMedCrossRef Castellano G, Bonilha L, Li LM, Cendes F. Texture analysis of medical images. Clin Radiol. 2004;59(12):1061–9.PubMedCrossRef
17.
go back to reference Eun NL, Kang D, Son EJ, Park JS, Youk JH, Kim JA, Gweon HM. Texture Analysis with 3.0-T MRI for Association of Response to Neoadjuvant Chemotherapy in Breast Cancer. Radiology. 2019;294(1):182718. Eun NL, Kang D, Son EJ, Park JS, Youk JH, Kim JA, Gweon HM. Texture Analysis with 3.0-T MRI for Association of Response to Neoadjuvant Chemotherapy in Breast Cancer. Radiology. 2019;294(1):182718.
18.
go back to reference Colakoglu B, Alis D, Yergin M. Diagnostic value of machine learning-based quantitative texture analysis in differentiating benign and malignant thyroid nodules. J Oncol. 2019;2019:6328329.PubMedPubMedCentralCrossRef Colakoglu B, Alis D, Yergin M. Diagnostic value of machine learning-based quantitative texture analysis in differentiating benign and malignant thyroid nodules. J Oncol. 2019;2019:6328329.PubMedPubMedCentralCrossRef
19.
go back to reference Kielar AZ, Chernyak V, Bashir MR, Do RK, Fowler KJ, Mitchell DG, Cerny M, Elsayes KM, Santillan C, Kamaya A, et al. LI-RADS 2017: An update. J Magn Reson Imaging. 2018;47(6):1459–74.PubMedPubMedCentralCrossRef Kielar AZ, Chernyak V, Bashir MR, Do RK, Fowler KJ, Mitchell DG, Cerny M, Elsayes KM, Santillan C, Kamaya A, et al. LI-RADS 2017: An update. J Magn Reson Imaging. 2018;47(6):1459–74.PubMedPubMedCentralCrossRef
20.
go back to reference Szczypinski PM, Strzelecki M, Materka A, Klepaczko A. MaZda--a software package for image texture analysis. Comput Methods Prog Biomed. 2009;94(1):66–76.CrossRef Szczypinski PM, Strzelecki M, Materka A, Klepaczko A. MaZda--a software package for image texture analysis. Comput Methods Prog Biomed. 2009;94(1):66–76.CrossRef
21.
go back to reference Yan L, Liu Z, Wang G, Huang Y, Liu Y, Yu Y, Liang C. Angiomyolipoma with minimal fat: differentiation from clear cell renal cell carcinoma and papillary renal cell carcinoma by texture analysis on CT images. Acad Radiol. 2015;22(9):1115–21.PubMedCrossRef Yan L, Liu Z, Wang G, Huang Y, Liu Y, Yu Y, Liang C. Angiomyolipoma with minimal fat: differentiation from clear cell renal cell carcinoma and papillary renal cell carcinoma by texture analysis on CT images. Acad Radiol. 2015;22(9):1115–21.PubMedCrossRef
22.
go back to reference Lee JH, Lee JM, Kim SJ, Baek JH, Yun SH, Kim KW, Han JK, Choi BI. Enhancement patterns of hepatocellular carcinomas on multiphasic multidetector row CT: comparison with pathological differentiation. Brit J Radiol. 2012;85(1017):E573–83.PubMedCrossRefPubMedCentral Lee JH, Lee JM, Kim SJ, Baek JH, Yun SH, Kim KW, Han JK, Choi BI. Enhancement patterns of hepatocellular carcinomas on multiphasic multidetector row CT: comparison with pathological differentiation. Brit J Radiol. 2012;85(1017):E573–83.PubMedCrossRefPubMedCentral
23.
go back to reference Chen WT, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, Wu CW. Recurrent hepatocellular carcinoma after hepatic resection: prognostic factors and long-term outcome. EJSO-Eur J Surg Onc. 2004;30(4):414–20.CrossRef Chen WT, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, Wu CW. Recurrent hepatocellular carcinoma after hepatic resection: prognostic factors and long-term outcome. EJSO-Eur J Surg Onc. 2004;30(4):414–20.CrossRef
24.
go back to reference Zhou H, Vallieres M, Bai HX, Su C, Tang H, Oldridge D, Zhang Z, Xiao B, Liao W, Tao Y, et al. MRI features predict survival and molecular markers in diffuse lower-grade gliomas. Neuro-Oncol. 2017;19(6):862–70.PubMedPubMedCentralCrossRef Zhou H, Vallieres M, Bai HX, Su C, Tang H, Oldridge D, Zhang Z, Xiao B, Liao W, Tao Y, et al. MRI features predict survival and molecular markers in diffuse lower-grade gliomas. Neuro-Oncol. 2017;19(6):862–70.PubMedPubMedCentralCrossRef
25.
go back to reference Holli-Helenius K, Salminen A, Rinta-Kiikka I, Koskivuo I, Bruck N, Bostrom P, Parkkola R. MRI texture analysis in differentiating luminal a and luminal B breast cancer molecular subtypes - a feasibility study. BMC Med Imaging. 2017;17(1):69.PubMedPubMedCentralCrossRef Holli-Helenius K, Salminen A, Rinta-Kiikka I, Koskivuo I, Bruck N, Bostrom P, Parkkola R. MRI texture analysis in differentiating luminal a and luminal B breast cancer molecular subtypes - a feasibility study. BMC Med Imaging. 2017;17(1):69.PubMedPubMedCentralCrossRef
26.
go back to reference Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278(2):563–77.PubMedCrossRef Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278(2):563–77.PubMedCrossRef
27.
go back to reference Mule S, Thiefin G, Costentin C, Durot C, Rahmouni A, Luciani A, Hoeffel C. Advanced hepatocellular carcinoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with Sorafenib. Radiology. 2018;288(2):445–55.PubMedCrossRef Mule S, Thiefin G, Costentin C, Durot C, Rahmouni A, Luciani A, Hoeffel C. Advanced hepatocellular carcinoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with Sorafenib. Radiology. 2018;288(2):445–55.PubMedCrossRef
28.
go back to reference Li Y, Yan C, Weng S, Shi Z, Sun H, Chen J, Xu X, Ye R, Hong J. Texture analysis of multi-phase MRI images to detect expression of Ki67 in hepatocellular carcinoma. Clin Radiol. 2019;74(10):813–9.PubMedCrossRef Li Y, Yan C, Weng S, Shi Z, Sun H, Chen J, Xu X, Ye R, Hong J. Texture analysis of multi-phase MRI images to detect expression of Ki67 in hepatocellular carcinoma. Clin Radiol. 2019;74(10):813–9.PubMedCrossRef
29.
go back to reference Lubner MG, Smith AD, Sandrasegaran K, Sahani DV, Pickhardt PJ. CT texture analysis: definitions, applications, biologic correlates, and challenges. Radiographics. 2017;37(5):1304–483.CrossRef Lubner MG, Smith AD, Sandrasegaran K, Sahani DV, Pickhardt PJ. CT texture analysis: definitions, applications, biologic correlates, and challenges. Radiographics. 2017;37(5):1304–483.CrossRef
30.
go back to reference Zhou W, Zhang L, Wang K, Chen S, Wang G, Liu Z, Liang C. Malignancy characterization of hepatocellular carcinomas based on texture analysis of contrast-enhanced MR images. J Magn Reson Imaging. 2017;45(5):1476–84.PubMedCrossRef Zhou W, Zhang L, Wang K, Chen S, Wang G, Liu Z, Liang C. Malignancy characterization of hepatocellular carcinomas based on texture analysis of contrast-enhanced MR images. J Magn Reson Imaging. 2017;45(5):1476–84.PubMedCrossRef
31.
go back to reference Fang WH, Li XD, Zhu H, Miao F, Qian XH, Pan ZL, Lin XZ. Resectable pancreatic ductal adenocarcinoma: association between preoperative CT texture features and metastatic nodal involvement. Cancer Imaging. 2020;20(171):17. Fang WH, Li XD, Zhu H, Miao F, Qian XH, Pan ZL, Lin XZ. Resectable pancreatic ductal adenocarcinoma: association between preoperative CT texture features and metastatic nodal involvement. Cancer Imaging. 2020;20(171):17.
32.
go back to reference Kaseb AO, Hassan M, Lacin S, Abdel-Wahab R, Amin HM, Shalaby A, Wolff RA, Yao J, Rashid A, Vennapusa B, et al. Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget. 2016;7(43):69916–26.PubMedPubMedCentralCrossRef Kaseb AO, Hassan M, Lacin S, Abdel-Wahab R, Amin HM, Shalaby A, Wolff RA, Yao J, Rashid A, Vennapusa B, et al. Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget. 2016;7(43):69916–26.PubMedPubMedCentralCrossRef
33.
go back to reference Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, Niki T, Shibahara J, Mori M, Makuuchi M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Modern Pathol. 2005;18(12):1591–8.CrossRef Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, Niki T, Shibahara J, Mori M, Makuuchi M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Modern Pathol. 2005;18(12):1591–8.CrossRef
34.
Metadata
Title
Texture analysis of MR images to identify the differentiated degree in hepatocellular carcinoma: a retrospective study
Authors
Mengmeng Feng
Mengchao Zhang
Yuanqing Liu
Nan Jiang
Qian Meng
Jia Wang
Ziyun Yao
Wenjuan Gan
Hui Dai
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-07094-8

Other articles of this Issue 1/2020

BMC Cancer 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine